Immuneering Reports Positive Phase 2a Results

Pranathi Perati's journey with pancreatic cancer began with a routine endoscopy that revealed a stage IIB diagnosis, which she attributes to her decision to follow through with the procedure despite initial doubts. Her treatment included the Whipple procedure, chemotherapy, and multiple surgeries, alongside participation in clinical trials that provided access to innovative therapies. Immuneering Corporation recently announced promising results from its Phase 2a study of IMM-1-104 in combination with modified FOLFIRINOX for first-line pancreatic cancer, achieving a 50% overall response rate, surpassing the historical benchmark of 32% for FOLFIRINOX alone. The company has raised nearly $14 million to support its research and plans to release further trial data in mid-2025. These advancements highlight the importance of clinical trials in offering new treatment options for cancer patients, as exemplified by Perati's experience. Both stories underscore the critical role of early detection and innovative therapies in improving outcomes for pancreatic cancer patients.